AUS
NZ
UK
CA
USA
IND
Highlights
- Revenue Surge: AstraZeneca’s total revenue rose by 21% to $54.1 billion, led by 19% growth in product sales and continued momentum in partnered medicines.
- Earnings & Dividend Boost: Core earnings per share (EPS) climbed 19% to $8.21, with an annual dividend increase of 7% to $3.10 per share.
- 2025 Outlook: The company forecasts high single-digit revenue growth and a low double-digit rise in Core EPS for FY 2025.
Pharmaceutical giant AstraZeneca PLC (LSE:AZN) has posted strong financial results for FY 2024, with total revenue soaring 21% to $54.1 billion at constant exchange rates. The remarkable growth was primarily fueled by a 19% increase in product sales, along with significant contributions from partnered medicines and milestone-driven collaboration revenue.
Therapeutic Segments Show Strong Growth
AstraZeneca’s revenue growth was broad-based across its key therapeutic areas:
- Oncology revenue climbed 24%, reflecting the increasing demand for its cancer treatments.
- Cardiovascular, Renal & Metabolism (CVRM) segment expanded by 20%, driven by strong sales in heart and kidney-related treatments.
- Respiratory & Immunology (R&I) grew 25%, signaling the company’s robust presence in lung and immune-related diseases.
- Vaccines & Immune Therapies (V&I) saw an 8% increase, highlighting steady demand in this segment.
- Rare Disease revenue advanced 16%, underscoring AstraZeneca’s commitment to treating complex, lesser-known conditions.
Earnings Growth and Increased Shareholder Returns
AstraZeneca also reported a 19% increase in Core EPS to $8.21, reflecting its strong operational performance and continued investment in research and development. To reward shareholders, the company declared a second interim dividend of $2.10 per share, bringing the total annual dividend to $3.10 per share, a 7% increase from the previous year. The company has also committed to further increasing the dividend in FY 2025.
Confident Outlook for 2025
Looking ahead, AstraZeneca has provided positive guidance for FY 2025:
- Total revenue is expected to grow by a high single-digit percentage.
- Core EPS is projected to rise by a low double-digit percentage.
The company remains focused on innovation, expanding market presence, and strategic collaborations, positioning itself for sustained long-term growth.
